Centers for Medicare and Medicaid Innovation; Drug Pricing and Medicare Parts B and D; Medicaid Funding; Medicare Advantage; Medicare Hospital/Provider Reimbursement Policy; Medicare Regulatory Reform; Medicare Shared Savings Program; 340B Drug Pricing Program
340B Drug Pricing Program; Alternative Payment Models; Anti-Kickback Statute Reform; Behavioral Health; COVID-19; Drug Pricing; Emergency Provider Relief Fund; Environmental Sustainability; FY 2024 Appropriations; Graduate Medical Education; Health Care Innovation; Health Equity/Social Determinants of Health; Health Sector Cybersecurity; Health Workforce; Mental Health; Post-Acute and Home Health Care Payments; Stark Law Reform/Modernization; Surprise Billing/Price Transparency; Telehealth/Digital Health; Value in Health Care Act; Value-Based Purchasing Reimbursement
Duration: November 1, 2007
to
present
General Issues: Medicare/Medicaid , Health Issues , Immigration , Taxation/Internal Revenue Code , Pharmacy , Budget/Appropriations
Spending: about $16,693,769 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2007: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Y
Y
Affiliated organizations: Aurora Health Care; Advocate Health Care
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, ADVOCATE AURORA HEALTH, INC. had in-house lobbyists. The report was filed on April 16.
Original Filing: 301550720.xml
Lobbying Issues
Centers for Medicare and Medicaid Innovation; Drug Pricing and Medicare Parts B and D; Medicaid Funding; Medicare Advantage; Medicare Hospital/Provider Reimbursement Policy; Medicare Regulatory Reform; Medicare Shared Savings Program; 340B Drug Pricing Program
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Drug Pricing Program; Alternative Payment Models; Anti-Kickback Statute Reform; Behavioral Health; COVID-19; Drug Pricing; Emergency Provider Relief Fund; Environmental Sustainability; FY 2024 Appropriations; Graduate Medical Education; Health Care Innovation; Health Equity/Social Determinants of Health; Health Sector Cybersecurity; Health Workforce; Mental Health; Post-Acute and Home Health Care Payments; Stark Law Reform/Modernization; Surprise Billing/Price Transparency; Telehealth/Digital Health; Value in Health Care Act; Value-Based Purchasing Reimbursement
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, ADVOCATE AURORA HEALTH, INC. had in-house lobbyists. The report was filed on Jan. 19.
Original Filing: 301529745.xml
Lobbying Issues
Centers for Medicare and Medicaid Innovation; Drug Pricing and Medicare Parts B and D; Medicaid Funding; Medicare Advantage; Medicare Hospital/Provider Reimbursement Policy; Medicare Regulatory Reform; Medicare Shared Savings Program; 340B Drug Pricing Program
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Drug Pricing Program; Alternative Payment Models; Anti-Kickback Statute Reform; Behavioral Health; COVID-19; Emergency Provider Relief Fund; Environmental Sustainability; FY 2024 Appropriations; Graduate Medical Education; Health Care Innovation; Health Equity/Social Determinants of Health; Health Sector Cybersecurity; Health Workforce; Mental Health; Post-Acute and Home Health Care Payments; Stark Law Reform/Modernization; Surprise Billing/Price Transparency; Telehealth/Digital Health; Value in Health Care Act; Value-Based Purchasing Reimbursement
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, ADVOCATE AURORA HEALTH, INC. had in-house lobbyists. The report was filed on Oct. 20, 2023.
Original Filing: 301509833.xml
Lobbying Issues
Centers for Medicare and Medicaid Innovation; Drug Pricing and Medicare Parts B and D; Medicaid Funding; Medicare Advantage; Medicare Hospital/Provider Reimbursement Policy; Medicare Regulatory Reform; Medicare Shared Savings Program; 340B Drug Pricing Program
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Drug Pricing Program; Alternative Payment Models; Anti-Kickback Statute Reform; Behavioral Health; COVID-19; Emergency Provider Relief Fund; Environmental Sustainability; FY 2024 Appropriations; Graduate Medical Education; Health Care Innovation; Health Equity/Social Determinants of Health; Health Sector Cybersecurity; Mental Health; Post-Acute and Home Health Care Payments; Stark Law Reform/Modernization; Surprise Billing/Price Transparency; Telehealth/Digital Health; Value in Health Care Act; Value-Based Purchasing Reimbursement; Workforce/Nursing/Allied Health Funding.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, ADVOCATE AURORA HEALTH, INC. had in-house lobbyists. The report was filed on July 19, 2023.
Original Filing: 301482001.xml
Lobbying Issues
Centers for Medicare and Medicaid Innovation; Drug Pricing and Medicare Parts B and D; Medicaid Funding; Medicare Advantage; Medicare Hospital/Provider Reimbursement Policy; Medicare Regulatory Reform; Medicare Shared Savings Program
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Drug Pricing Program; Alternative Payment Models; Anti-Kickback Statute Reform; Behavioral Health; COVID-19; Emergency Provider Relief Fund; Environmental Sustainability; FY 2024 Appropriations; Graduate Medical Education; Health Care Innovation; Health Equity/Social Determinants of Health; Health Sector Cybersecurity; Health Workforce; Mental Health; Post-Acute and Home Health Care Payments; Stark Law Reform/Modernization; Surprise Billing/Price Transparency; Telehealth/Digital Health; Value in Health Care Act; Value-Based Purchasing Reimbursement
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, ADVOCATE AURORA HEALTH, INC. had in-house lobbyists. The report was filed on April 20, 2023.
Original Filing: 301460071.xml
Lobbying Issues
Value-Based Purchasing Reimbursements; Post-Acute and Home-Health Care Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Stark Law Reform/Modernization; Value-Based Purchasing Reimbursements; Post-Acute and Home Health Care Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; Surprise Billing/Price Transparency; Anti-Kickback Statute Reform; COVID-19; Value in Health Care Act; Mental Health; Health Workforce; Emergency Provider Relief Fund; Health Sector Cybersecurity; Health Equity/Social Determinants of Health; Environmental Sustainability.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, ADVOCATE AURORA HEALTH, INC. had in-house lobbyists. The report was filed on Jan. 19, 2023.
Original Filing: 301432454.xml
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home HealthCare Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; Surprise Billing/Price Transparency; Anti-Kickback Statute Reform; COVID-19; Value in Health Care Act; Mental Health; Health Workforce; Emergency Provider Relief Fund; Health Sector Cybersecurity; Heath Equity/Social Determinants of Health; Environmental Sustainability.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home HealthCare Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; Surprise Billing/Price Transparency; Anti-Kickback Statute Reform; COVID-19; Value in Health Care Act; Mental Health; Health Workforce; Emergency Provider Relief Fund; Health Sector Cybersecurity; Health Equity/Social Determinants of Health; Environmental Sustainability.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
ADVOCATE AURORA HEALTH, INC. amended a lobbying report for in-house lobbying in Q32022 on Oct. 20, 2022
Original Filing: 301414783.xml
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home HealthCare Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; Surprise Billing/Price Transparency; Anti-Kickback Statute Reform; COVID-19; Value in Health Care Act; Mental Health; Health Workforce; Emergency Provider Relief Fund; Health Sector Cybersecurity; Heath Equity/Social Determinants of Health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home HealthCare Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; Surprise Billing/Price Transparency; Anti-Kickback Statute Reform; COVID-19; Value in Health Care Act; Mental Health; Health Workforce; Emergency Provider Relief Fund; Health Sector Cybersecurity; Health Equity/Social Determinants of Health.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, ADVOCATE AURORA HEALTH, INC. had in-house lobbyists. The report was filed on Oct. 17, 2022.
Original Filing: 301405813.xml
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home HealthCare Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; Surprise Billing/Price Transparency; Anti-Kickback Statute Reform; COVID-19; Value in Health Care Act; Mental Health; Health Workforce; Emergency Provider Relief Fund; Health Sector Cybersecurity; Heath Equity/Social Determinants of Health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home HealthCare Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; Surprise Billing/Price Transparency; Anti-Kickback Statute Reform; COVID-19; Value in Health Care Act; Mental Health; Health Workforce; Emergency Provider Relief Fund; Health Sector Cybersecurity; Health Equity/Social Determinants of Health.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, ADVOCATE AURORA HEALTH, INC. had in-house lobbyists. The report was filed on July 18, 2022.
Original Filing: 301382955.xml
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home HealthCare Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; Surprise Billing/Price Transparency; Anti-Kickback Statute Reform; COVID-19; Value in Health Care Act; Mental Health; Health Workforce; Emergency Provider Relief Fund; Health Sector Cybersecurity; Heath Equity/Social Determinants of Health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home HealthCare Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; Surprise Billing/Price Transparency; Anti-Kickback Statute Reform; COVID-19; Value in Health Care Act; Mental Health; Health Workforce; Emergency Provider Relief Fund; Health Sector Cybersecurity; Health Equity/Social Determinants of Health.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, ADVOCATE AURORA HEALTH, INC. had in-house lobbyists. The report was filed on April 18, 2022.
Original Filing: 301358395.xml
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home HealthCare Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; Surprise Billing/Price Transparency; Anti-Kickback Statute Reform; COVID-19; Value in Health Care Act; Mental Health; Health Workforce; Emergency Provider Relief Fund; Health Sector Cybersecurity; Heath Equity/Social Determinants of Health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home HealthCare Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; Surprise Billing/Price Transparency; Anti-Kickback Statute Reform; COVID-19; Value in Health Care Act; Mental Health; Health Workforce; Emergency Provider Relief Fund; Health Sector Cybersecurity; Health Equity/Social Determinants of Health.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, ADVOCATE AURORA HEALTH, INC. had in-house lobbyists. The report was filed on Jan. 18, 2022.
Original Filing: 301325123.xml
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home HealthCare Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; Surprise Billing; Anti-Kickback Statute Reform; COVID-19; Value in Health Care Act; Mental Health; Health Workforce; Emergency Provider Relief Fund.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home HealthCare Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; Surprise Billing; Anti-Kickback Statute Reform; COVID-19; Value in Health Care Act; Mental Health; Health Workforce; Emergency Provider Relief Fund.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, ADVOCATE AURORA HEALTH, INC. had in-house lobbyists. The report was filed on Oct. 20, 2021.
Original Filing: 301309003.xml
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home HealthCare Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; Surprise Billing; Anti-Kickback Statute Reform; COVID-19; Value in Health Care Act; Health Equity; Workforce Occupational Health and Safety.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home HealthCare Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; Surprise Billing; Anti-Kickback Statute Reform; COVID-19; Value in Health Care Act; Health Equity; Workforce Occupational Health and Safety.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2021
In Q2, ADVOCATE AURORA HEALTH, INC. had in-house lobbyists. The report was filed on July 16, 2021.
Original Filing: 301278225.xml
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home HealthCare Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; Surprise Billing; Anti-Kickback Statute Reform; COVID-19; Value in Health Care Act; Health Equity; Workforce Occupational Health and Safety; Provider Relief Funding.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home HealthCare Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; Surprise Billing; Anti-Kickback Statute Reform; COVID-19; Value in Health Care Act; Health Equity; Workforce Occupational Health and Safety; Provider Relief Funding.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2021
ADVOCATE AURORA HEALTH, INC. amended a lobbying report for in-house lobbying in Q12021 on April 20, 2021
Original Filing: 301265319.xml
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home HealthCare Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; Surprise Billing; Anti-Kickback Statute Reform; CREATES Act; COVID-19; Value in Health Care Act; Health Equity.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home HealthCare Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; Surprise
Billing; Anti-Kickback Statute Reform; CREATES Act; COVID-19; Value in Health Care Act; Health Equity.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, ADVOCATE AURORA HEALTH, INC. had in-house lobbyists. The report was filed on Feb. 15, 2021.
Original Filing: 301248313.xml
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education;Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home HealthCare Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; Surprise
Billing; Anti-Kickback Statute Reform; CREATES Act; COVID-19; Value in Health Care Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education;Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home HealthCare Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; Surprise
Billing; Anti-Kickback Statute Reform; CREATES Act; COVID-19; Value in Health Care Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, ADVOCATE AURORA HEALTH, INC. had in-house lobbyists. The report was filed on Jan. 20, 2021.
Original Filing: 301238443.xml
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home Health Care Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; S 433/HR 2753 Home Health Payment Innovation Act of 2019; S 296/HR 2150 Home Health Care Planning Improvement Act of 2019; Maternal Mortality; H.R. 1897/S. 916 - Mothers and Offspring Mortality and Morbidity Awareness Act (MOMMAs Act); Surprise Billing; Anti-Kickback Statute Reform; CREATES Act; HR 1499 Protecting Consumer Access to Generic Drugs; Accountable Care Organizations; HR 987 Strengthening Health Care and Lowering Prescription Drug Costs; COVID-19; Value in Health Care Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home Health Care Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; S 433/HR 2753 Home Health Payment Innovation Act of 2019; S 296/HR 2150 Home Health Care Planning Improvement Act of 2019; Maternal Mortality; Surprise Billing; Anti-Kickback Statute Reform; CREATES Act; HR 1499 Protecting Consumer Access to Generic Drugs; Accountable Care Organizations; HR 987 Strengthening Health Care and Lowering Prescription Drug Costs; COVID-19; Value in Health Care Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, ADVOCATE AURORA HEALTH, INC. had in-house lobbyists. The report was filed on Oct. 19, 2020.
Original Filing: 301213416.xml
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home Health Care Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; S 433/HR 2753 Home Health Payment Innovation Act of 2019; S 296/HR 2150 Home Health Care Planning Improvement Act of 2019; Maternal Mortality; H.R. 1897/S. 916 - Mothers and Offspring Mortality and Morbidity Awareness Act (MOMMAs Act); Surprise Billing; Anti-Kickback Statute Reform; CREATES Act; HR 1499 Protecting Consumer Access to Generic Drugs; HR 987 Strengthening Health Care and Lowering Prescription Drug Costs; COVID-19; Accountable Care Organizations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home Health Care Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; S 433/HR 2753 Home Health Payment Innovation Act of 2019; S 296/HR 2150 Home Health Care Planning Improvement Act of 2019; Maternal Mortality; H.R. 1897/S. 916 - Mothers and Offspring Mortality and Morbidity Awareness Act (MOMMAs Act); Surprise Billing; Anti-Kickback Statute Reform; CREATES Act; HR 1499 Protecting Consumer Access to Generic Drugs; HR 987 Strengthening Health Care and Lowering Prescription Drug Costs; COVID-19; Accountable Care Organizations.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, ADVOCATE AURORA HEALTH, INC. had in-house lobbyists. The report was filed on July 20, 2020.
Original Filing: 301194927.xml
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home Health Care Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; S 433/HR 2753 Home Health Payment Innovation Act of 2019; S 296/HR 2150 Home Health Care Planning Improvement Act of 2019; Maternal Mortality; H.R. 1897/S. 916 - Mothers and Offspring Mortality and Morbidity Awareness Act (MOMMAs Act); Surprise Billing; Anti-Kickback Reform; CREATES Act; HR 1499 Protecting Consumer Access to Generic Drugs; HR 987 Strengthening Health Care and Lowering Prescription Drug Costs; COVID-19
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home Health Care Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; S 433/HR 2753 Home Health Payment Innovation Act of 2019; S 296/HR 2150 Home Health Care Planning Improvement Act of 2019; Maternal Mortality; H.R. 1897/S. 916 - Mothers and Offspring Mortality and Morbidity Awareness Act (MOMMAs Act); Surprise Billing; Anti-Kickback Reform; CREATES Act; HR 1499 Protecting Consumer Access to Generic Drugs; HR 987 Strengthening Health Care and Lowering Prescription Drug Costs; COVID-19
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, ADVOCATE AURORA HEALTH, INC. had in-house lobbyists. The report was filed on April 20, 2020.
Original Filing: 301174573.xml
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home Health Care Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; S 433/HR 2753 Home Health Payment Innovation Act of 2019; S 296/HR 2150 Home Health Care Planning Improvement Act of 2019; Maternal Mortality; H.R. 1897/S. 916 - Mothers and Offspring Mortality and Morbidity Awareness Act (MOMMAs Act); Surprise Billing; Anti-Kickback Reform; CREATES Act; HR 1499 Protecting Consumer Access to Generic Drugs; HR 987 Strengthening Health Care and Lowering Prescription Drug Costs; COVID-19
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home Health Care Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Telehealth/Digital Health; S 433/HR 2753 Home Health Payment Innovation Act of 2019; S 296/HR 2150 Home Health Care Planning Improvement Act of 2019; Maternal Mortality; H.R. 1897/S. 916 - Mothers and Offspring Mortality and Morbidity Awareness Act (MOMMAs Act); Surprise Billing; Anti-Kickback Reform; CREATES Act; HR 1499 Protecting Consumer Access to Generic Drugs; HR 987 Strengthening Health Care and Lowering Prescription Drug Costs; COVID-19
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, ADVOCATE AURORA HEALTH, INC. had in-house lobbyists. The report was filed on Jan. 21, 2020.
Original Filing: 301124394.xml
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home Health Care Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Digital Health; S 433/HR 2753 Home Health Payment Innovation Act of 2019; S 296/HR 2150 Home Health Care Planning Improvement Act of 2019; Maternal Mortality; H.R. 1897/S. 916 - Mothers and Offspring Mortality and Morbidity Awareness Act (MOMMAs Act); Surprise Billing; Anti-Kickback Reform; CREATES Act; HR 1499 Protecting Consumer Access to Generic Drugs; HR 987 Strengthening Health Care and Lowering Prescription Drug Costs
Agencies Lobbied
U.S. Senate
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home Health Care Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Medicaid Funding; Health Care Innovation; Digital Health; S 433/HR 2753 Home Health Payment Innovation Act of 2019; S 296/HR 2150 Home Health Care Planning Improvement Act of 2019; Maternal Mortality; H.R. 1897/S. 916 - Mothers and Offspring Mortality and Morbidity Awareness Act (MOMMAs Act); Surprise Billing; Anti-Kickback Reform; CREATES Act; HR 1499 Protecting Consumer Access to Generic Drugs; HR 987 Strengthening Health Care and Lowering Prescription Drug Costs
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
ADVOCATE AURORA HEALTH, INC. amended a lobbying report for in-house lobbying in Q32019 on Feb. 3, 2020
Original Filing: 301131117.xml
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home Health Care Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Oppose Site Neutral Cust and 340B Cuts; Medicaid Funding; Health Care Innovation; Digital Health; Regulatory Relief/Waivers; S 433/HR 2753 Home Health Payment Innovation Act of 2019; S 296/HR 2150 Home Health Care Planning Improvement Act of 2019; Maternal Mortality; H.R. 1897/S. 916 - Mothers and Offspring Mortality and Morbidity Awareness Act (MOMMAs Act); Surprise Billing; Anti-Kickback Reform; CREATES Act; HR 1499 Protecting Consumer Access to Generic Drugs; HR 987 Strengthening Health Care and Lowering Prescription Drug Costs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Behavioral health and opioids; Value-based health care; Transparency in health care billing; Violence and trauma prevention; treatment, and funding; Maternal mortality; 340B drug pricing program; Health care innovation; Digital health; Drug pricing; Drug Shortages; Access to care; Preserving the Affordable Care Act protections; Surprise billing; H.R. 965 CREATES Act of 2019; H.R. 1897, MOMMA'S Act; Maternal Morbidity; HR 1897/S. 916 Mothers and Offspring Mortality and Morbidity Awareness Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, ADVOCATE AURORA HEALTH, INC. had in-house lobbyists. The report was filed on Oct. 18, 2019.
Original Filing: 301070527.xml
Lobbying Issues
340B Drug Pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Centers for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-Based Purchasing Payments; Post-Acute and Home Health Care Payments; Drug Pricing and Medicare Parts B and D; Medicare Regulatory Reform; Oppose Site Neutral Cust and 340B Cuts; Medicaid Funding; Health Care Innovation; Digital Health; Regulatory Relief/Waivers; S 433/HR 2753 Home Health Payment Innovation Act of 2019; S 296/HR 2150 Home Health Care Planning Improvement Act of 2019; Maternal Mortality; H.R. 1897/S. 916 - Mothers and Offspring Mortality and Morbidity Awareness Act (MOMMAs Act); Surprise Billing; Anti-Kickback Reform; CREATES Act; HR 1499 Protecting Consumer Access to Generic Drugs; HR 987 Strengthening Health Care and Lowering Prescription Drug Costs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Behavioral health and opioids; Value-based health care; Transparency in health care billing; Violence and trauma prevention; treatment, and funding; Maternal mortality; 340B drug pricing program; Health care innovation; Digital health; Drug pricing; Drug Shortages; Access to care; Preserving the Affordable Care Act protections; Surprise billing; H.R. 965 CREATES Act of 2019; H.R. 1897, MOMMA'S Act; Maternal Morbidity; HR 1897/S. 916 Mothers and Offspring Mortality and Morbidity Awareness Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, ADVOCATE AURORA HEALTH, INC. had in-house lobbyists. The report was filed on July 22, 2019.
Original Filing: 301057860.xml
Lobbying Issues
340B drug pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Center for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-based purchasing/payments; Post-acute and home health care payments; Drug pricing and Medicare Parts B and D; Medicare regulatory reform; Oppose site neutral cuts and 340B cuts; Medicaid funding; Health care innovation; Digital health; Regulatory relief/waivers; S. 433 Home Health Payment Innovation Act of 2019; S. 296 Home Health Care Planning Improvement Act of 2019; Maternal Morbidity; HR 1897/S. 916 Mothers and Offspring Mortality and Morbidity Awareness Act, Surprise Billing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Behavioral health and opioids; Value-based health care; Transparency in health care billing; Violence and trauma prevention; treatment, and funding; Maternal mortality; 340B drug pricing program; Health care innovation; Digital health; Drug pricing; Drug Shortages; Access to care; Preserving the Affordable Care Act protections; Surprise billing; H.R. 965 CREATES Act of 2019; H.R. 1897, MOMMA'S Act; Maternal Morbidity; HR 1897/S. 916 Mothers and Offspring Mortality and Morbidity Awareness Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, ADVOCATE AURORA HEALTH, INC. had in-house lobbyists. The report was filed on April 12, 2019.
Original Filing: 301024859.xml
Lobbying Issues
340B drug pricing Program; Medicare Shared Savings Program; Medicare Advantage; Alternative Payment Models; Graduate Medical Education; Center for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-based purchasing/payments; Post-acute and home health care payments; Drug pricing and Medicare Parts B and D; Medicare regulatory reform; Oppose site neutral cuts and 340B cuts; Medicaid funding; Antikickback reform; Health care innovation; Digital health; Regulatory relief/waivers; S. 433 Home Health Payment Innovation Act of 2019; S. 296 Home Health Care Planning Improvement Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Behavioral health and opioids; Value-based health care; Transparency in health care billing; Violence and trauma prevention; treatment, and funding; Maternal mortality; 340B drug pricing program; Health care innovation; Digital health; Drug pricing; Drug Shortages; Access to care; Preserving the Affordable Care Act protections; Surprise billing; H.R. 965 CREATES Act of 2019; H.R. 1897, MOMMA'S Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, ADVOCATE AURORA HEALTH, INC. had in-house lobbyists. The report was filed on Jan. 21, 2019.
Original Filing: 301012331.xml
Lobbying Issues
340B Program; Medicare Shared Savings Program; 2019 Home Health Rule; Medicare Advantage; Graduate Medical Education; Center for Medicare and Medicaid Innovation; Stark Law Reform/Modernization; Value-based purchasing/payments; H.R. 2118 Medical Device Servicing and Safety Accountability Act; Post acute care payment; Drug pricing; Medicare regulatory reform; Oppose site neutral cuts and 340B cuts in OPPS rule; 2019 OPPS Rule; Medicaid funding; Anti-kickback reform; Healthcare innovation; Digital health; Regulatory relief/waivers.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Behavioral health and opioids; Value-based health care; Transparency in health care billing; Drug pricing; Health care regulatory reform; Violence
and trauma prevention and treatment; Maternal mortality; 340B drug pricing; Healthcare innovation relief/waivers; Digital health.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, ADVOCATE AURORA HEALTH, INC. had in-house lobbyists. The report was filed on Oct. 22, 2018.
Original Filing: 300997845.xml
Lobbying Issues
340B Program; Medicare Three Day Stay Rule; Medicare Shared Savings Program; Medicare Conditions of Participation; 2019 Home Health Rule; Medicare Advantage; Graduate Medical Education; Center for Medicare and Medicaid Innovation; IMPACT Act implementation; HR 4392 To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; Stark Law Reform/Modernization; Value-based purchasing/payments; HR 2118 Medical Device Servicing Safety and Accountability Act; Inpatient prospective payment system rule; Post acute care payment; Drug pricing; Medicare regulatory reform; Oppose OPPS site neutral cuts; MSSP digital signature change; MACRA; 2019 Physician fee schedule; 2019 OPPS Rule; Medicaid funding; Anti-kickback reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Behavioral health and opioids; Value-based health care; Transparency in health care billing; Drug pricing; Health care regulatory reform; Violence
and trauma prevention and treatment.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
ADVOCATE AURORA HEALTH, INC. filed a lobbying registration on Sept. 19, 2018 for in-house lobbying efforts, effective April 1, 2018.
Original Filing: 300981827.xml
Issue(s) they said they’d lobby about: Medicare, Medicaid, pharmaceutical issues, health care related issues. .
2nd Quarter, 2018
In Q2, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on July 19, 2018.
Original Filing: 300969617.xml
Lobbying Issues
340B Program; Medicare Three Day Stay Rule; Medicare Shared Savings Program; Medicaid Provider Tax; Medicare Conditions of Participation; Home Health; Medicare Advantage; Graduate Medical Education; Center for Medicare and Medicaid Innovation; Bundled Payment for Care Improvement - Advanced Model; IMPACT Act Implementation; HR 4392 To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B discount drug program shall have no force or effect, and for other purposes; Stark Law Reform/Modernization; Value based-purchasing/payments; HR 2118 Medical Device Servicing Safety Accountability Act; Inpatient prospective payment system rule; CHIP rescission cuts.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Behavioral health, opioids, maternal and child health; Value-based health care; Transparency in health care billing; Drug pricing; Health care regulatory reform.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on April 20, 2018.
Original Filing: 300957539.xml
Lobbying Issues
340B Program; CHIP Reauthorization; Medicare Three Day Stay Rule; Medicare Shared Savings Program; PAMA Implementation; Medicaid Provider Tax; Medicare Condition and Participation; Home Health; Medicare Advantage; Graduate Medical Education; Center for Medicare and Medicaid Innovation; Bundled Payment for Care Improvement- Advanced Model; IMPACT Act Implementation; HR 4392, To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Affordable Care Act (ACA) implementation; Cost-sharing reduction payments; Behavioral health, opioids, maternal and child health.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
ADVOCATE HEALTH CARE amended a lobbying report for in-house lobbying in Q42017 on April 19, 2018
Original Filing: 300950360.xml
Lobbying Issues
Prescription drug costs and pricing; Medicare Access and CHIP reauthorization Act (MACRA) implementation; 340B Program; Medicaid/Federal Medical Assistance Percentages(FMAP); 2018 hospital Outpatient Prospective Payment System Rule; 2018 Home Health Payment Rule; CHIP Reauthorization; Medicare Three Day Stay Rule; Medicare Shared Savings Program; Behavioral Health Issues in Medicaid Program; 2018 Medicare Quality Payment Program Rule; PAMA Implementation; HR 4392, To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Drug Pricing; Affordable Care Act (ACA) implementation
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax Code and Reform; HR 1 The Tax Cuts and Jobs Act provisions related to taxation and bonds, and charitable donations
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2017
In Q4, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on Jan. 15, 2018.
Original Filing: 300923740.xml
Lobbying Issues
Prescription drug costs and pricing; Medicare Access and CHIP reauthorization Act (MACRA) implementation; 340B Program; Medicaid/Federal Medical Assistance Percentages(FMAP); 2018 hospital Outpatient Prospective Payment System Rule; 2018 Home Health Payment Rule; CHIP Reauthorization; Medicare Three Day Stay Rule; Medicare Shared Savings Program; Behavioral Health Issues in Medicaid Program; 2018 Medicare Quality Payment Program Rule; PAMA Implementation.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Drug Pricing; Affordable Care Act (ACA) implementation
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax Code and Reform; HR 1 The Tax Cuts and Jobs Act provisions related to taxation and bonds, and charitable donations
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
In Q3, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on Oct. 20, 2017.
Original Filing: 300915673.xml
Lobbying Issues
Prescription drug costs and pricing; Medicare Access and CHIP reauthorization Act (MACRA) implementation; 340B Program; Medicaid/Federal Medical Assistance Percentages(FMAP); S. 428 ACE Kids Act of 2017; Medicaid Provisions in Senate Health Care Reform Bills; 2018 hospital Outpatient Prospective Payment System Rule; 2018 Home Health Payment Rule; CHIP Reauthorization; HR 1628 Better Care Reconciliation Act; Medicare Three Day Stay Rule; Medicare Shared Savings Program; Behavioral Health Issues in Medicaid Program; 2018 Medicare Quality Payment Program Rule
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Drug Pricing; Affordable Care Act (ACA) implementation; Health Care Reform Senate Bills; H.R. 1628 Better Care Reconciliation Act
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on July 20, 2017.
Original Filing: 300895155.xml
Lobbying Issues
IMPACT Act implementation; Prescription drug costs and pricing; Medicare Access and CHIP reauthorization Act (MACRA) implementation; home health pre-claim review demonstration; 340B Program; Medicaid/Federal Medical Assistance Percentages(FMAP); S. 428 ACE Kids Act of 2017
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Drug Pricing; Affordable Care Act (ACA); Health Care Reform; Behavioral Health; H.R. 1628-the American Health Care Act; H.R. 2118 Medical Device Servicing Safety and Accountability Act; Opioid/ substance use disorder.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on April 20, 2017.
Original Filing: 300875058.xml
Lobbying Issues
IMPACT Act implementation; Accountable Care Organizations/Medicare Shared Savings Program; Pay for Value/Delivery System Reform; Post-acute care/skilled nursing facilities access; Home Health Care payment rates; Prescription drug costs and pricing; Medicare Access and CHIP reauthorization Act (MACRA) implementation; Center for Medicare and Medicaid Services Technical Expert Panel nominations; home
health pre-claim review demonstration; 340B Program; Medicaid/Federal Medical Assistance Percentages (FMAP); GME Funding; Medicare Advantage.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Drug Pricing; Affordable Care Act (ACA); Health Care Reform; Behavioral Health; H.R. 1628- the American Health Care Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on Jan. 18, 2017.
Original Filing: 300849450.xml
Lobbying Issues
IMPACT Act implementation; Accountable Care Organizations/Medicare Shared Savings Program; Pay for Value/Delivery System Reform; Post-acute care/skilled nursing facilities access; Home Health Care payment rates; Prescription drug costs and pricing; Alternative Payment models including bundling; Medicare Access and CHIP reauthorization Act (MACRA) implementation; Center for Medicare and Medicaid Services Technical Expert Panel nominations; home health pre-claim review demonstration; Section 1115 Waivers; H.R. 3298 the Medicare Post-Acute Care Value-Based Purchasing Act of 2015; H.R. 6043 Fair Drug Pricing Act of 2015; Protecting Access to Medicare Act Implementation.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2016
In Q3, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on Oct. 20, 2016.
Original Filing: 300837596.xml
Lobbying Issues
IMPACT Act implementation; Accountable Care Organizations/Medicare Shared Savings Program; Pay for Value/Delivery System Reform; S. 298/H.R. 546 - ACE Kids Act of 2015; Site neutral payments; Post-acute care/skilled nursing facilities access; Home Health Care payment rates; Medicare Advantage Program; 340B Program; Prescription drug costs and pricing; Alternative Payment models including bundling; Medicare Access and CHIP reauthorization Act (MACRA) implementation; Center for Medicare and Medicaid Services Technical Expert Panel nominations; Medicare Evidence and Coverage Committee nominations; home health pre-claim review demonstration.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2016
In Q2, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on July 20, 2016.
Original Filing: 300821803.xml
Lobbying Issues
Graduate Medical Education Payment Issues; Accountable Care Organizations/Medicare Shared Savings Program; Pay for Value/Delivery System Reform; S. 298/H.R. 546 - ACE Kids Act of 2015; Site neutral payments; Post-acute care/skilled nursing facilities access; Home Health Care payment rates; Medicare Advantage Program; 340B Program; Prescription drug costs and pricing; Alternative Payment models; Medicare Access and CHIP reauthorization Act (MACRA) implementation; Medicare Star Ratings System Delay; PAMA Implementation
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on April 19, 2016.
Original Filing: 300796271.xml
Lobbying Issues
Graduate Medical Education Payment Issues; Accountable Care Organizations/Medicare Shared Savings Program; Pay for Value/Delivery System Reform; S. 298/H.R. 546 - ACE Kids Act of 2015; Site neutral payments; Post-acute care/skilled nursing facilities access; Home Health Care payment rates; Medicare Advantage Program; 340B Program; Prescription drug costs and pricing; Alternative Payment models; Finance Committee healthcare working group effort; Medicare Access and CHIP reauthorization Act (MACRA) implementation.
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on Jan. 20, 2016.
Original Filing: 300780168.xml
Lobbying Issues
Graduate Medical Education Payment Issues; Accountable Care Organizations/Medicare Shared Savings Program; Pay for Value/Delivery System Reform; S. 298/H.R. 546 - ACE Kids Act of 2015; site neutral payments; post-acute care/skilled nursing facilities access; Medicare three-day rule, observation stays policies; Home Health Care payment rates; Medicare Advantage Program; Two midnight and Medicare short stay policies; 340B Program; H.R. 2156 - Medicare Audit Improvement Act of 2015; Prescription drug costs; Recovery Audit Contractor Program Reform; Alternative Payment models; Drug Pricing.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on Oct. 20, 2015.
Original Filing: 300761495.xml
Lobbying Issues
Graduate Medical Education Payment Issues; Accountable Care Organizations/Medicare Shared Savings Program; Quality of Care Measurements/Pay for Value/Delivery System Reform; S. 298/H.R. 546 - ACE Kids Act of 2015; site neutral payments; post-acute care/skilled nursing facilities access; Medicare three-day rule, observation stays policies; Home Health Care payment rates; ICD 10 Implementation; Medicare Advantage Program; Postacute care/skilled nursing facility funding; two midnight and Medicare short stay policies; 340B Program; H.R. 2156 - Medicare Audit Improvement Act of 2015; CHIP Reauthorization; Recovery Audit Contractor Program Reform; Alternative Payment models.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on July 20, 2015.
Original Filing: 300740848.xml
Lobbying Issues
Graduate Medical Education Payment Issues; Implementation of the Patient Protection & Affordable Care Act (P.L. 111-148); Accountable Care Organizations/Medicare Shared Savings Program; Quality of Care Measurements/Pay for Value/Delivery System Reform; S. 298/H.R. 546 - ACE Kids Act of 2015; site neutral payments; post-acute care/skilled nursing facilities access; Medicare three-day rule, observation stays policies; Home Health Care payment rates; ICD 10 Implementation; Medicare Advantage Program; Postacute care/skilled nursing facility funding; two midnight and Medicare short stay policies; 340B Program; H.R. 2156 - Recovery Audit Contractor Program Reform; CHIP Reauthorization; SGR Reform (H.R. 2).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Population health issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on April 20, 2015.
Original Filing: 300725879.xml
Lobbying Issues
Graduate Medical Education Payment Issues; Implementation of Patient Protection and Affordable Care Act (P.L. 111-148); Accountable Care Organizations/Medicare Shared Savings Program; Quality of Care Measurements/Pay for Value/Delivery System Reform; H.R. 546 -ACE Kids Act of 2015; site neutral payments; post-acute care/skilled nursing facilities access; Medicare three-day rule, observation stays policies; Home Health Care payment rates; ICD 10 Implementation; Medicare Advance Program; Postacute care/skilled nursing facility funding; two midnight and Medicare short stay policies; 340B Program; Recovery Audit Contractor Program Reform; CHIP Reauthorization; Federal Medical Assistance Percentage Formula; Value Based Purchasing; SGR Reform (H.R. 2).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical malpractice issues; population health issues; pharmaceutical cost issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on Jan. 20, 2015.
Original Filing: 300704910.xml
Lobbying Issues
FY 2015 Graduate Medical Education Funding.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 4015 - SGR Repeal and Medicare Provider Payment Modernization Act of 2014; H.R. 4302 - Protecting Access to Medicare Act of 2014; S. 1871 - SGR Repeal and Medicare Beneficiary Access Act of 2013; S. 2000 - SGR Repeal and Medicare Provider Payment Modernization Act of 2014; S. 2110 - Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014; S. 2122 - Responsible Medicare SGR Repeal and Beneficiary Access Improvement Access Act of 2014; Graduate Medical Education Payment Issues; Implementation of the Patient Protection & Affordable Care Act (P.L. 111-148); Accountable Care Organizations/Medicare Shared Savings Program; Quality of Care Measurements/Pay for Value/Delivery System Reform; H.R. 49030 - ACE Kids Act of 2014; H.R. 3698 - The Two Midnight Delay Act of 2013; H.R. 1250/S. 1012 - The Medicare Audit Improvement Act of 2013; S. 2082 - The Two-Midnight Rule Coordination and Improvement Act of 2014; site neutral payments; post-acute care/skilled nursing facilities access; Medicare three-day rule. observation stays policies; Medicaid Primary Care Payment Parity; Home Health Care; ICD 10 Implementation; Hospital Improvements for Payment Act; Medicare Advantage Program; Postacute care.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2014
In Q3, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on Oct. 21, 2014.
Original Filing: 300689310.xml
Lobbying Issues
FY 2015 Graduate Medical Education Funding.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 4015 - SGR Repeal and Medicare Provider Payment Modernization Act of 2014; H.R. 4302 -Protecting Access to Medicare Act of 2014; S. 1871 - SGR Repeal and Medicare Beneficiary Access Act of 2013; S. 2000 - SGR Repeal and Medicare Provider Payment Modernization Act of 2014; S. 2110 - Medicare SGR Repeal and Beneficiary Accesss Improvment Act of 2014; S. 2122 - Responsible Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014; Graduate Medical Education Payment Issues; Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Accountable Care Organizations/Medicare Shared Savings Program; Quality of Care Measurements/Pay for Value/Delivery System Reform; H.R. 4930 - ACE Kids Act of 2014; H.R. 3698 - The Two Midnight Delay Act of 2013; H.R. 1250/S. 1012 - The Medicare Audit Improvement Act of 2013; S. 2082 - The Two-midnight Rule Coordination and Improvement Act of 2014; site neutral payments; post-acute care/skilled nursing facilities access; Medicare three-day rule, observation stays policies; Medicaid Primary Care Payment Parity; Home Health Care; and ICD 10 Implementation.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2014
ADVOCATE HEALTH CARE amended a lobbying report for in-house lobbying in Q22014 on July 18, 2014
Original Filing: 300660802.xml
Lobbying Issues
FY 2015 Graduate Medical Education Funding
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 4015 - SGR Repeal and Medicare Provider Payment Modernization Act of 2014; H.R. 4302 - Protecting Access to Medicare Act of 2014; S. 1871 - SGR Repeal and Medicare Beneficiary Access Act of 2013; S. 2000 - SGR Repeal and Medicare Provider Payment Modernization Act of 2014; S. 2110 - Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014; S. 2122 - Responsible Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014; Medicare Reimbursement; Sustainable Growth Rate/Physician Fee Schedule Fix; Federal Medical Assistance Percentage (FMAP); Graduate Medical Education Payment Issues; Implementation of the Patient Protection & Affordable Care Act (P.L. 111-148); Accountable Care Organizations/Medicare Shared Savings Program; Quality of Care and Measurements/Pay for Value/Delivery System Reform; Impact of Sequestration on Medicare Program; Medicaid children's hospital care coordination network creation for complex conditions; H.R. 3698 - The Two-Midnight Delay Act of 2013; H.R. 1250/S. 1012 - The Medicare Audit Improvement Act of 2013; S. 2082 - The Two-Midnight Rule Coordination and Improvement Act of 2014; site neutral payments; post-acute/skilled nursing facilities access; Medicare three-day rule, observation stays policies; Medicaid Primary Care Payment Parity.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2014
In Q2, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on July 17, 2014.
Original Filing: 300660255.xml
Lobbying Issues
FY 2015 Graduate Medical Education Funding
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 4015 - SGR Repeal and Medicare Provider Payment Modernization Act of 2014; H.R. 4302 - Protecting Access to Medicare Act of 2014; S. 1871 - SGR Repeal and Medicare Beneficiary Access Act of 2013; S. 2000 - SGR Repeal and Medicare Provider Payment Modernization Act of 2014; S. 2110 - Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014; S. 2122 - Responsible Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014; Medicare Reimbursement; Sustainable Growth Rate/Physician Fee Schedule Fix; Federal Medical Assistance Percentage (FMAP); Graduate Medical Education Payment Issues; Implementation of the Patient Protection & Affordable Care Act (P.L. 111-148); Accountable Care Organizations/Medicare Shared Savings Program; Quality of Care and Measurements/Pay for Value/Delivery System Reform; Impact of Sequestration on Medicare Program; Medicaid children's hospital care coordination network creation for complex conditions; H.R. 3698 - The Two-Midnight Delay Act of 2013; H.R. 1250/S. 1012 - The Medicare Audit Improvement Act of 2013; S. 2082 - The Two-Midnight Rule Coordination and Improvement Act of 2014; site neutral payments; post-acute/skilled nursing facilities access; Medicare three-day rule, observation stays policies; Medicaid Primary Care Payment Parity.
Agencies Lobbied
U.S. Senate
1st Quarter, 2014
In Q1, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on April 18, 2014.
Original Filing: 300642271.xml
Lobbying Issues
FY 2015 Graduate Medical Education Funding
Lobbying Issues
H.R. 4015 - SGR Repeal and Medicare Provider Payment Modernization Act of 2014; H.R. 4302 - Protecting Access to Medicare Act of 2014; S. 1871 SGR Repeal and Medicare Beneficiary Access Act of 2013; S. 2000 - SGR Repeal and Medicare Provider Payment Modernization Act of 2014; S. 2110 - Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014; S. 2122 - Responsible Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014; (continued next page) Medicare Reimbursement; Sustainable Growth Rate/Physician Fee Schedule Fix; Federal Medical Assistance Percentage (FMAP); Graduate Medical Education Payment Issues; Implementation of the Patient Protection & Affordable Care Act (P.L. 111-148); Accountable Care Organizations; Quality of Care and Measurements/Pay for Value/Delivery System Reform; Impact of Sequestration on Medicare Program; Medicare three-day rule; Medicaid children's hospital care coordination network creation for complex conditions; H.R. 3698 - The Two-Midnight Delay Act of 2013; H.R. 1250/S. 1012 - The Medicare Audit Improvement Act of 2013; S. 2082 - The Two-Midnight Rule Coordination and Improvement Act of 2014; site neutral payments; post-acute care/skilled nursing facilities access and medicare three-day rule and observation stays policies.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2013
In Q4, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on Jan. 21, 2014.
Original Filing: 300628620.xml
Lobbying Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Impact of sequestration on health care programs; American Taxpayer Relief Act (H.R. 8); Nursing and health care workforce shortage issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Reimbursement; Sustainable Growth Rate/Physician Fee Schedule Fix; Federal Medical Assistance Percentage (FMAP); Graduate Medical Education Payment Issues; Implementation of the Patient Protection & Affordable Care Act (P.L. 111-48); Accountable Care Organizations; Home Health; Hospital Related Durable Medical Equipment; Trauma Care; Quality of Care and Measurements/Pay for Value/Delivery System Reform; Impact of Sequestration on Medicare Program; (continued)Medicare Readmissions Penalty Program; Medicare fraud and abuse issues; Delay of DSH cuts; Medicare RAC audits; Post acute care/SNF access; Medicare inpatient payment policy; Medicare three-day rule; Medicare coverage issues; and Medicare critical access hospitals; Medicare two-midnight rule; Medicaid children's hospital care coordination network creation; Medicare observation status policy.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2014 Funding for Healthcare and Nursing Workforce and Health Workforce Commission
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on Oct. 21, 2013.
Original Filing: 300606506.xml
Lobbying Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Impact of sequestration on health care programs; American Taxpayer Relief Act (H.R. 8); Nursing and health care workforce shortage issues; Charity care issues; HIPAA.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Reimbursement; Sustainable Growth Rate/Physcian Fee Schedule Fix; Federal Medical Assistance Percentage (FMAP); Graduate Medical Education Payment Issues; Implementation of the Patient Protection & Affordable Care Act (P.L. 111-148); Accountable Care Organizations; Home Health; Hospital-Related Durable Medical Equipment; Trauma Care; Quality of Care and Measurements/Pay for Value/Delivery System Reform; Impact of Sequestration on Medicare Program; (continued)Medicare Readmissions Penalty Program; Medicare fraud and abuse issues; Delay of DSH cuts; Medicare RAC audits; Post acute care/SNF access; Medicare inpatient payment policy; Medicare three-day rule; Medicare coverage issues; and Medicare critical access hospitals.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2014 Funding for Healthcare and Nursing Workforce and Health Workforce Commission
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
ADVOCATE HEALTH CARE filed a lobbying registration on Aug. 14, 2013 for in-house lobbying efforts, effective Aug. 15, 2013.
Original Filing: 300589097.xml
Issue(s) they said they’d lobby about: Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Impact of Sequestration of Health Care programs; American Taxpayer Relief Act (H.R.8); HITECH Act (P.L. 111-5) electronic medical records; Medicare reimbursement; Sustainable Growth Rate/Physician Fee Fix; Federal Medical Assistance Percentage; Graduate Medical Education Payment Issues; Accountable Care Organizations; Qualify of Care and Measurement/Pay for Value/Delivery System Reform; Medicaid Expansion Issues; etc. .
3rd Quarter, 2013
ADVOCATE HEALTH CARE filed a lobbying registration on July 29, 2013 for in-house lobbying efforts, effective July 30, 2013.
Original Filing: 300587910.xml
Issue(s) they said they’d lobby about: Implementation of the Patient Protection and Affordable Care Act (P.L.111-148); Impact of Sequestration on Health Care programs; American Taxpayer Relief Act (H.R.8); HITECH Act (P.L. 111-5) electronic medical records; Medicare reimbursement; Sustainable Growth Rate/Physician Fee Fix; Federal Medical Assistance Percentage; Graduate Medical Education Payment Issues; Accountable Care Organizations; Quality of Care and Measurements/Pay for Value/Delivery System Reform; Medicaid Expansion Issues; etc. .
2nd Quarter, 2013
In Q2, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on July 19, 2013.
Original Filing: 300577983.xml
Lobbying Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Impact of Sequestration of Health Care programs; American Taxpayer Relief Act (H.R. 8); Nursing and health care workforce; Charity care issues; HITECH Act (P.L. 111-5) electronic medical records
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Reimbursement; Sustainable Growth Rate/Physician Fee Schedule Fix; Federal Medical Assistance Percentage (FMAP); Graduate Medical Education Payment Issues; Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Accountable Care Organizations; Home Health; Hospital-Related Durable Medical Equipment; Trauma Care; Quality of Care and Measurements/Pay for Value/Delivery System Reform; Impact of Sequestration on the Medicare Program; (continued)American Taxpayer Relief Act (H.R. 8); Medicare Readmissions Penalty Program; Medicaid expansion issues; Medicare fraud and abuse issues; Delay of DHS cuts; Medicare RAC audits; Medicare hospital conditions of participation
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2014 Funding for Healthcare and Nursing Workforce and Health Workforce Commission
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on April 22, 2013.
Original Filing: 300562707.xml
Lobbying Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Impact of Sequestration on Health Care programs; American Taxpayer Relief Act (H.R. 8); Nursing and health care workforce shortage issues; Charity care issues; HITECH Act (P.L. 111-5) electronic medical records.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Reimbursement; Sustainable Growth Rate/Physician Fee Schedule Fix; Federal Medical Assistance Percentage (FMAP); Graduate Medical Education Payment Issues; Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Accountable Care Organizations; Home Health; Hospital-Related Durable Medical Equipment; Trauma Care; Quality of Care and Measurements/Pay for Value/Delivery System Reform; Impact of Sequestration on the Medicare Program; (continued)American Taxpayer Relief Act (H.R.8); Medicare Readmissions Penalty Program; Medicaid expansion issues; Medicare fraud and abuse issues.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
ADVOCATE HEALTH CARE amended a lobbying report for in-house lobbying in Q42012 on Jan. 22, 2013
Original Filing: 300541325.xml
Lobbying Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Medical Malpractice; H.R. 2245/S. 296 - Preserving Access to Life-Saving Medications Act of 2011; Drug Shortages; H.R. 5 - Protecting Access to Healthcare Act; Impact of Sequestration on Health Care Programs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Reimbursement; Sustainable Growth Rate/Physician Fee Schedule Fix; Federal Medical Assistance Percentage (FMAP); Graduate Medical Education Payment Issues; Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Accountable Care Organizations; Home Health; Hospital-Related Durable Medical Equipment; Trauma Care; Quality of Care and Measurements/Pay for Value/Delivery System Reform; Impact of Sequestration on Medicare Program.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on Jan. 22, 2013.
Original Filing: 300538013.xml
Lobbying Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Medical Malpractice; H.R. 2245/S. 296 - Preserving Access to Life-Saving Medications Act of 2011; Drug Shortages; H.R. Protecting Access to Healthcare Act; Impact of Sequestration on Health Care Programs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Reimbursement; Sustainable Growth Rate/Physician Fee Schedule Fix; Federal Medical Assistance Percentage (FMAP); Graduate Medical Education Payment Issues; Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Accountable Care Organizations; Home Health; Hospital-Related Durable Medical Equipment; Trauma Care; Quality of Care and Measurement/Pay for Value/Delivery System Reform.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on Oct. 22, 2012.
Original Filing: 300518059.xml
Lobbying Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Medical Malpractice; H.R.2245/S.296 - Preserving Access to Life-Saving Medications Act of 2011; Drug Shortages; H.R. 5 - Protecting Access to Healthcare Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Reimbursement; Sustainable Growth Rate/Physician Fee Schedule Fix; Federal Medical Assistance Percentage (FMAP); Graduate Medical Education Payment Issues; Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Accountable Care Organizations; Home Health; Hospital-Related Durable Medical Equipment; Trauma Care; Quality of Care and Measurement/Pay for Value/Delivery System Reform; Impact of Sequestration on Medicare Program.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on July 17, 2012.
Original Filing: 300487284.xml
Lobbying Issues
FY 2013 House and Senate Labor, Health and Human Services and Education, and Related Agencies Appropriations Bill; Funding for Nursing Workforce and Health Diversity Professional Programs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Medical Malpractice; H.R. 2245/S. 296 - Preserving Access to Life-Saving Medications Act of 2011; Drug Shortages; H.R. 5 - Protecting Access to Healthcare Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Reimbursement; Sustainable Growth Rate/Physician Fee Schedule Fix; Federal Medical Assistance Percentage (FMAP); Graduate Medical Education Payment Issues; Implementation of the Patient Protection and Affordable Care Act (P.L.111-148); Accountable Care Organizations; Home Health; Hospital-Related Durable Medical Equipment; Trauma Care; Quality of Care and Measurement/Pay for Value/Delivery System Reform.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on April 20, 2012.
Original Filing: 300474367.xml
Lobbying Issues
FY 2013 House and Senate Labor, Health and Human Services and Education, and related Agencies appropriations bill; Funding for the Nursing Workforce and Health Diversity Professional Programs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Medical Malpractice; H.R. 2245/S. 296 - Preserving Access to Life-Saving Medications Act of 2011; Drug Shortages; H.R. 5 - Protecting Access to Healthcare Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Reimbursement; Sustainable Growth Rate/Physician Fee Schedule Fix; Federal Medical Assistance Percentage (FMAP); Graduate Medical Education payment issues; Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Accountable Care Organizations; Home Health; Hospital Related Durable Medical Equipment; Trauma Care.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on Jan. 19, 2012.
Original Filing: 300443695.xml
Lobbying Issues
FY 2012 House and Senate Labor, Health and Human Services and Education, and Related Agencies Appropriations Bill; Funding for Nursing Workforce and Health Diversity Professional Programs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Medical Malpractice; H.R. 2245/S.296 - Preserving Access to Life-Saving Medications Act of 2011; Drug Shortages.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Reimbursement; Sustainable Growth Rate/Physician Fee Schedule Fix; Federal Medical Assistance Percentage (FMAP); Graduate Medical Education Payment Issues; Health Information Technology; Implementation of the Patient Protection & Affordable Care Act (P.L. 111-148); Accountable Care Organizations; Home Health; HAIs and Readmissions Policies; Innovation Proposals; CMS Medicare Conditions of Participation; Requirements for Skilled Nursing Facility Admission; Trauma Care.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2011
In Q3, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on Oct. 20, 2011.
Original Filing: 300429241.xml
Lobbying Issues
FY 2012 House and Senate Labor, Health and Human Services and Education, and Related Agencies Appropriations bill.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Medical Malpractice; H.R. 2245/S.296-Preserving Access to Life-Saving Medications Act of 2011; Drug Shortages.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Reimbursement; Sustainable Growth Rate/Physician Fee Schedule Fix; Federal Medical Assistance Percentage (FMAP); Medical Education Payment Issues; Health Information Technology; Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Issues Related to Accountable Care Organizations; Home Health; HAIs and Readmissions Policies; Innovations Proposals.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on July 20, 2011.
Original Filing: 300403462.xml
Lobbying Issues
FY 2012 House and Senate Labor, Health and Human Services and Education, and related Agencies appropriations bill.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Medical Malpractice; H.R. 2245/S. 296 - Preserving Access to Life-Saving Medications Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Reimbursement; Sustainable Growth Rate/Physician Fee Schedule Fix; Federal Medical Assistance Percentage (FMAP); Medical Education Payment Issues; Health Information Technology; Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Issues Related to Accountable Care Organizations; Home Health; HAIs and Readmissions Policies; Innovation Proposals.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on April 20, 2011.
Original Filing: 300375050.xml
Lobbying Issues
FY 2011 House and Senate Labor, Health and Human Services, and Education, Related Agencies Appropriations Bill.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Medical Malpractice.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Reimbursement; Sustainable Growth Rate/Physician Fee Schedule Fix; Temporary Increase and Reform of the Federal Medical Assistance Percentage (FMAP); Medical Education Payment Issues; Health Information Technology; Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); issues related to accountable care organizations; Home Health; HAIs and Readmissions Policies; Innovation Proposals.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2010
In Q4, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on Jan. 20, 2011.
Original Filing: 300350212.xml
Lobbying Issues
FY 2011 House and Senate Labor, Health and Human Services and Education, and Related Agencies Appropriations Bill; FY 2011 Energy and Water Appropriations Bill.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
State Children's Health Insurance Program; Health Care Reform and Access to Care for Uninsured; Issues Related to Funding of Nursing Workforce Program; Health Care Reform; Health Information Technology; H.R.4872, the Health Care and Education Reconciliation Act of 2010; the Patient Protection and Affordable Care Act (P.L. 111-148).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Reimbursement; Sustainable Growth Rate/Physician Fee Schedule Fix; Temporary Increase and Reform of the Federal Medical Assistance Percentage (FMAP); Medicare Advantage Reimbursement; Indirect Medical Education Issues; Hospital Charity Care Issues; Medicare Health Technology Adoption Incentives; Health Information Technology; H.R. 3691, Medicare Physician Payment Reform Act; H.R., 4872. the Health Care and Education Reconciliation Act of 2010; the Patient Protection & AffordableCare Act (P.L. 111-148); issues related to accountable care organizations; issues related to the Center for Medicare Innovation; FY 2011 Inpatient Prospective Payment System.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
In Q3, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on Oct. 20, 2010.
Original Filing: 300327428.xml
Lobbying Issues
FY 2011 House and Senate Labor, Health and Human Services and Education, and Related Agencies Appropriations Bill; FY 2011 Energy and Water Appropriations Bill.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
State Children's Health Insurance Program; Health Care Reform and Access to Care for Uninsured; Issues Related to Fund of Nursing Workforce Program; Health Care Reform; Health Information Technology; H.R. 4872, the Health Care and Education Reconciliation Act of 2010; the Patient Protection and Affordable Care Act (P.L. 111-148).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Reimbursement; Sustainable Growth Rate/Physician Fee Schedule Fix; Temporary Increase and Reform of the Federal Medical Assistance Percentage (FMAP); Medicare Advantage Reimbursement; Indirect Medical Education Issues; Hospital Charity Care Issues; Medicare Health Technology; Adoption Incentives; Health Information Technology; H.R. 3961, Medicare Physician Payment Reform Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010; the Patient Protection and Affordable Care Act (P.L. 111-148); issues related to accountable care organizations; issues related to the Center for Medicare Innovation; FY 2011 Inpatient Prospective Payment System.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2010
In Q2, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on July 20, 2010.
Original Filing: 300301895.xml
Lobbying Issues
FY 2011 House and Senate Labor, Health and Human Services and Education, and Related Agencies Appropriations Bill: FY 2011 Energy and Water Appropriations Bill.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
State Children's Health Insurance Program; Health Care Reform and Access to Care for Uninsured; Issues Related to Funding of Nursing Workforce Program; Health Care Reform, Health Information Technology; H.R. 4872, the Health Care and Education Reconciliation Act of 2010; the Patient Protection and Affordable Care Act (P.L. 111-148.)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Reimbursement; Sustainable Growth Rate/Physician Fee Schedule Fix; Temporary Increase and Reform of the Federal Medical Assistance Percentage (FMAP); Medicare Advantage Reimbursement; Indirect Medical Education Issues; Hospital Charity Care Issues; Medicare Health Technology Adoption Incentives; Health Information Technology; H.R. 3961, Medicare Physician Payment Reform Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010; the Patient Protection & AffordableCare Act (P.L. 111-148); issues related to accountable care organizations; FY 2011 Inpatient Prospective Payment System.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2010
In Q1, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on April 20, 2010.
Original Filing: 300274186.xml
Lobbying Issues
FY 2011 House and Senate Labor, Health and Human Services and Education, and Related Agencies Appropriations Bill; FY 2011 Energy and Water Appropriations Bill.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
State Children's Health Insurance Program; Health Care Reform and Access to Care for Uninsured; Issues Related to Funding of Nursing Workforce Program; Health Care Reform, Health Information Technology; H.R. 3200 - America's Affordable Health Choices Act of 2009; S. 1679 - Affordable Health Choices Act; H.R. 3590, the Patient Protection Affordable Care Act; H.R. 3962, the Affordable Health Care for America Act; H.R. 3780, Health Care Reform Provisions; H.R. 4872, the Health Care and EducationAffordability Reconciliation Act of 2010; the Patient Protection and Affordable Care Act (P.L.111-148).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Reimbursement; Sustainable Growth Rate/Physician Fee Schedule Fix; Temporary Increase and Reform of the Federal Medical Assistance Percentage (FMAP); Medicare Advantage Reimbursement; Indirect Medical Education Issues; Hospital Charity Care Issues; Medicare Adoption Incentives; Health Information Technology; H.R. 3961, Medicare Physician Payment Reform Act; H.R. 4872, the Health Care and Education Affordability Reconciliation Act of 2010; the Patient Protection and Affordable Care Act (P.L. 111-148).
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2009
In Q4, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on Jan. 19, 2010.
Original Filing: 300238473.xml
Lobbying Issues
FY 2010 House and Senate Labor, Health and Human Services and Education, and Related Agencies Appropriations Bill; FY 2010 House and Senate Commerce, Justice, Science, and Related Agencies Appropriations Act, 2010 (H.R. 2847); H.R. 3288, Consolidated Appropriations Act of 2010; Full House and Senate Labor, Health and Human Services and Education Bill.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
State Children's Health Insurance Program; Health Care Reform and Access to Care for Uninsured; Issues Related to Funding of Nursing Workforce Program; Health Care Reform; Health Information Technology; H.R. 3200 - America's Affordable Health Choices Act of 2009; S. 1679 - Affordable Health Choices Act; H.R. 3590, the Patient Protection Affordable Care Act; H.R.3962, the Affordable Health Care for America Act; H.R. 3780, Health Care Reform Provisions.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Reimbursement; Sustainable Growth Rate/Physician Fee Schedule Fix; Temporary Increase and Reform of the Federal Medical Assistance Percentage (FMAP); Medicare Advantage Reimbursement; Indirect Medical Education Issues; Hospital Charity Care Issues; Medicare Adoption Incentives; Health Information Technology; H.R. 3961, Medicare Physician Payment Reform Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2009
In Q3, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on Oct. 20, 2009.
Original Filing: 300217492.xml
Lobbying Issues
FY 2010 House and Senate Labor, Health and Human Services and Education, and Related Agencies Appropriations Bill; FY 2010 House and Senate Commerce, Justice, Science and Related Agencies Appropriations Act, 2010 (H.R.2847).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
State Children's Health Insurance Program; Health Care Reform and Access to Care for Uninsured; Issues Related to Funding of Nursing Workforce Program; Health Care Reform, Health Information Technology; H.R. 3200 - America's Affordable Health Choices Act of 2009; S. 1679 - Affordable Health Choices Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Reimbursement; Sustainable Growth Rate/Physician Fee Schedule Fix; Temporary Increase and Reform of the Federal Medical Assistance Percentage (FMAP); Medicare Advantage Reimbursement; Indirect Medical Education Issues; Hospital Charity Care Issues; Medicare Adoption Incentives; Health Information Technology.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2009
In Q2, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on July 16, 2009.
Original Filing: 300181011.xml
Lobbying Issues
FY 2009 and FY 2010 Labor, Health and Human Services and Education, and Related Agencies Appropriations Bill; FY 2010 House (H.R. 2847) and Senate Commerce Justice Science Appropriations Bill.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
State Children's Health Insurance Program; Health Care Reform and Access to Care for Uninsured; Issues Related to Funding of the Nursing Workforce Program; Health Care Reform; Health Information Technology.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Reimbursement; Sustainable Growth Rate/Physician Fee Schedule Fix; Temporary Increase and Reform of the Federal Medical Assistance Percentage (FMAP); Medicare Advantage Reimbursement; Indirect Medical Education Issues; Hospital Charity Care Issues; Medicare Adoption Incentives; Health Information Technology.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2009
In Q1, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on April 20, 2009.
Original Filing: 300160815.xml
Lobbying Issues
FY 2009 and FY 2010 Labor, Health and Human Services and Education, and Related Agencies Appropriations Bill; FY 2009 and FY 2010 Commerce Justice Science Appropriations Bill; Stimulus Package; Supplemental Appropriations
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
State Children's Health Insurance Program; Health Care Reform and Access to Care for Uninsured.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Reimbursement; Illinois' Hospital Assessment Program; Sustainable Growth Rate/Physician Fee Schedule Fix; Temporary Increase and Reform of the Federal Medical Assistance Percentage (FMAP).
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2008
In Q4, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on Jan. 19, 2009.
Original Filing: 300127145.xml
Lobbying Issues
FY 2009 Labor, Health and Human Services and Education, and Related Agencies Appropriations Bill; FY 2009 Commerce Justice Science Appropriations Bill; FY 2009 Defense Appropriations Bill.
Stimulus Package; Supplemental Appropriations.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.20, The Melanie Blocker-Stokes Postpartum Depression Research and Care Act; State Childrens Health Insurance Program; S.1375, The MOTHERS Act; Mom's Opportunity to Access Health, Education, Research and Support for Postpartum Depression Act; H.R. 677, Nursing School Capacity Act; Health Care Reform and Access to Care for Uninsured.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Reimbursement; Illinois Hospital Assessment Program; Sustainable Growth Rate/Physician Fee Schedule Fix; Hospital Compare Data; H.R. 1845/S. 1428, Medicare Durable Medical Equipment Access Act; H.R. 621, Home Oxygen Patient Protection Act; Medicare Moratoriums and H.R. 5613, Protecting the Medicare Safety Act of 2008; H.R. 5268/S. 2620, providing temporary increase in Federal Matching Assistance Percentage; H.R. 6331, The Medicare Improvements for Patients and Provider Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2008
ADVOCATE HEALTH CARE amended a lobbying report for in-house lobbying in Q32008 on Nov. 26, 2008
Original Filing: 300112100.xml
Lobbying Issues
Medical Liability Reform
Uninsured
Hospital Capital Investments
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Labor--HHS FY Appropriations
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicaid Reimbursement
Medicare Reimbursement
Illinois Hospital Assessment Program
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax exempt status of not for profit hospitals
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2008
In Q3, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on Oct. 20, 2008.
Original Filing: 300106117.xml
Lobbying Issues
Medical Liability Reform
Uninsured
Hospital Capital Investments
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Labor--HHS FY Appropriations
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicaid Reimbursement
Medicare Reimbursement
Illinois Hospital Assessment Program
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax exempt status of not for profit hospitals
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2008
In Q2, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on July 21, 2008.
Original Filing: 300080784.xml
Lobbying Issues
Medical Liability Reform
Uninsured
Hospital Capital Investments
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Labor---HHS FY Appropriations
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicaid Reimbursement
Medicare Reimbursement
Illinois Hospital Assessment Program
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax exempt status of fot for profit hospitals
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2008
In Q1, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on April 18, 2008.
Original Filing: 300045411.xml
Lobbying Issues
Medical Liability Reform
Uninsured
Hospital Capital Investments
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Labor--HHS FY Appropriations
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicaid Reimbursement
Medicare Reimbursement
Illinois Hospital Assessment Program
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax exempt status of not for profit hospitals
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
0th Quarter, 2007
In MM, ADVOCATE HEALTH CARE had in-house lobbyists. The report was filed on Aug. 3, 2007.
Original Filing: 200045151.xml
Lobbying Issues
Medical Liability Reform
Uninsured/SCHIP
Hospital Billing Issues
Hospital Capital Investments
Lobbying Issues
Labor-HHS FY Appropriations
Lobbying Issues
Medicaid Reimbursement
Medicare Reimbursement
Lobbying Issues
Tax exempt status of non-profit hospitals
Type of Issue
Taxation/Internal Revenue Code
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...